



# FAPA 2018

The 27th Federation of Asian  
Pharmaceutical Associations Congress  
MANILA, PHILIPPINES 24-27 OCTOBER 2018

## Is there any clue for paclitaxel-induced hypersensitivity reactions?

Roongthip Tangsahasakri<sup>1</sup>, and Pattama Jainan<sup>2</sup>

<sup>1</sup>Senior pharmacist Rajavithi Hospital

<sup>2</sup>Pharmacist Rajavithi Hospital

Correspondence: [rtangsaqha@gmail.com](mailto:rtangsaqha@gmail.com)

**Keywords:** paclitaxel-induced hypersensitivity reactions, clue, risk factors

### Abstract:

**Objectives:** One of the most potentially serious toxicities of paclitaxel is the development of hypersensitivity reactions (HSR). Mostly HSR occur at the first or second cycle of paclitaxel infusions. So far we still don't have any clue to determine risk factors for paclitaxel-induced HSR. The aim of this study is to identify factors affecting paclitaxel-induced hypersensitivity reactions.

**Methods:** All patients treated with paclitaxel at our hospital between January 2014 and December 2015 were retrospectively evaluated. All the patients were treated to prevent hypersensitivity reactions, with prophylactic regimens. Data collected include patient demographic, BMI, cancer type, concurrent disease, allergy history, chemotherapy regimens, paclitaxel doses, premedication regimens and documented events of hypersensitivity reactions and severity.

**Results:** A total of 1132 patients received paclitaxel 5152 times. 48 patients (4.24%) 70 times found to have HSR from paclitaxel. The severity of HSR mostly was grade 2. Premedication used in this study was divided into 2 groups. Group1 dexamethasone was given orally 6-24 hr. before treatment. Group2 iv. dexamethasone 10-20 mg was given 30 minutes before paclitaxel. In HSR group, HSR occurred 29.17% (14 from 48 patients, 20 times) in group1 and 70.83% (34 from 48 patients, 50 times) in group2. Agriculture patient had higher incidence of HSR (OR 2.55, 95%CI: 1.20-5.43). Lung (14 from 187) and cervical (9 from 141) cancer patients had higher risk of HSR than other cancer.

**Conclusion:** An agriculture career patients, lung and cervical cancer patients had higher risk to HSR. Premedication regimen, given oral dexamethasone 6-24 hour before paclitaxel had less HSR.



[www.fapa.asia/fapa2018/](http://www.fapa.asia/fapa2018/)

 [fb.com/FAPA2018](https://www.facebook.com/FAPA2018)

